The present invention describes novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells. The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells. The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.
Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.
Researchers at the National Cancer Institute (NCI) have developed a technology that provides methods of performing adoptive cell transfer (ACT), an immunotherapeutic approach for cancer treatment, by administering a heterodimeric Interleukin 15/Interleukin 15 receptor alpha (IL-15/IL-15Rα) complex (hetlL-15) in the absence of lymphodepletion, thereby eliminating any lymphodepletion-associated detrimental side effects.
The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.
The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Acetalax is a previously FDA approved drug that has been used as a topical laxative but is being repurposed here as an onco-therapy because of its cytotoxic effects on a number of TNBC and other cancer cell lines.
Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished. The National Cancer Institute Laboratory of Experimental Immunology seeks parties interested in licensing a topical antibiotic formulation to accelerate wound healing.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for mesothelin targeting Recombinant Immunotoxins (RITs). These RITs have been engineered by site specific modification with polyethylene glycol (PEG) to have an increased serum half-life, while maintaining high cytotoxicity and have greatly improved anti-tumor activity.
Researchers at the National Cancer Institute (NCI) have developed a combination of immunoadjuvants and immune checkpoint inhibitors to stimulate an immune response against cancer. The combination therapy has been tested in xenograft models and shown successful for both treatment of an existing tumor and resistance to re-challenge. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
Available for licensing and co-development are antibody-drug conjugates (ADC) that incorporate one of two novel human CD56 antibodies, known as m900 and m906, in combination with a known cytotoxic drug, pyrrolobenzodiazepine (PBD).
Researchers at the National Cancer Institute (NCI) have developed an invention describing the binding domain (G2BD) for the ubiquitin-conjugating enzyme Ube2G2 in the gp78 ubiqutin ligase protein. The invention involves modulating the interaction between the gp78 protein and the conjugating enzyme Ube2G2. Interruption of this interaction will block degradation from the endoplasmic reticulum (ER), resulting in ER stress, unfolded protein response, and, ultimately, apoptosis in some cancer cells. The NCI seeks licensing and/or co-development partners for this invention.
Researchers at the National Cancer Institute (NCI) have developed a method to improve the function of therapeutic engineered T cells used for Adoptive T Cell Therapy (ACT) for various cancers and diseases through the co-expression of Interleukin-15 (IL-15) and IL-21 by a flexible linker to the cell membrane. Researchers at the NCI seek licensing for this invention.
The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target HIF-2a in cancer.
The National Cancer Institute (NCI) seeks licensees for a collection of novel T-cell receptors (TCRs) that target the Epstein Barr Virus Latent Membrane Protein 2 (EBV-LMP2). The TCRs are being developed as therapeutics for treatment of lymphomas and epithelial cancers.
The National Cancer Institute (NCI) seeks licensees for a collection of T-cell receptors (TCRs) that specifically target the CD20 antigen expressed in B-lymphoid malignancies such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCRs are being developed as therapeutics for the treatment of lymphomas and leukemias.
Researchers at the National Cancer Institute (NCI) have isolated T cell receptors (TCRs) that target specific mutations in the epidermal growth factor receptor (EGFR). The mutated protein recognized by these TCRs is frequently expressed in non-small cell lung cancer (NSCLC). These TCRs can be used for a variety of therapeutic applications, including engineered adoptive cell immunotherapy. Researchers at the NCI seek licensing and/or co-development research collaborations for these novel T cell receptors that recognize EGFR mutations.
It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use.
Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the University of Illinois in Chicago, have identified a number of small peptidomimetic compounds that bind to Ras proteins with nanomolar affinity. NCI’s Cancer and Inflammation Program seeks partners interested in licensing or co-development of synthetic, highly potent cell-permeable inhibitors of Ras that bind to the protein directly.
Scientists at the National Cancer Institute (NCI) have discovered a bacterial exonuclease VII (ExoVII) inhibitor that increases the potency of widely used quinolone antibiotics targeting prokaryotic type IIA topoisomerases. NCI seeks research co-development partners and/or licensees for the development of ExoVII inhibitors as new antibiotic adjuvants to boost the efficacy of quinolone antibiotics and/or restore the susceptibility of resistant bacteria.
Researchers at the National Cancer Institute discovered small-molecule compounds whose activity against HIV-1 integrase mutants confer greater resistance than currently approved INSTIs. Preliminary DMPK and ADME studies have been completed by the NCI researchers. The National Cancer Institute seeks partners to commercialize this class of compounds through licensing or co-development.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of small molecule inhibitors of the Eph receptor tyrosine kinase for Eph growth-dependent solid tumors such as colorectal cancer.